首页> 外文期刊>Endocrine journal >Prognosis and prognostic factors of differentiated thyroid carcinoma after the appearance of metastasis refractory to radioactive iodine therapy
【24h】

Prognosis and prognostic factors of differentiated thyroid carcinoma after the appearance of metastasis refractory to radioactive iodine therapy

机译:放射性碘治疗难治性转移灶出现后分化型甲状腺癌的预后及预后因素

获取原文
获取原文并翻译 | 示例
           

摘要

Differentiated thyroid carcinomas (DTCs) are generally indolent, but few therapeutic strategies are available after a metastatic recurrence that is refractory to radioactive iodine (RAI) therapy. Molecular-target therapy has shown promising results for DTCs with RAI-refractory recurrence. However, not all RAI-refractory recurrences are progressive, and even those that are progressive may not be immediately life-threatening. Here we investigated the prognosis and prognostic factors of 74 DTC patients (52 females, 22 males) in whom RAI-refractory metastases appeared. The five-year and 10-year cause-specific survival (CSS) rates of the 74 patients (8-82 yrs of age; median age at the detection of metastases, 61 yrs) were 95% and 70%, respectively, and the older patients (≥ 60 yrs, n=38) and male patients were significantly more likely to die of carcinoma. Also in multivariate analysis, older age (≥ 60 years) and male gender were independent predictors of carcinoma-related death. Taken together, our data indicate that RAI-refractory metastases of older patients and male patients are more progressive than those of other patients. Further studies are necessary to clarify the appropriate indications for molecular-target therapy for RAI-refractory and progressive metastases.
机译:分化型甲状腺癌(DTC)通常是惰性的,但是在放射性碘(RAI)治疗难以治愈的转移性复发后,几乎没有可用的治疗策略。分子靶向治疗已显示具有RAI难治性复发的DTC的前景广阔。但是,并非所有的RAI难治性复发都是进行性的,即使是那些进行性的复发也可能不会立即危及生命。在这里,我们调查了74例DAI患者(52例女性,22例男性)的RAI难治性转移出现的预后和预后因素。 74名患者(8-82岁;发现转移灶的中位年龄为61岁)的5年和10年病因特异性生存(CSS)率分别为95%和70%,而老年患者(≥60岁,n = 38)和男性患者死于癌症的可能性明显更高。同样在多变量分析中,年龄较大(≥60岁)和男性是癌症相关死亡的独立预测因子。综上所述,我们的数据表明,老年患者和男性患者的RAI难治性转移灶比其他患者更为进展。有必要进行进一步的研究以阐明针对RAI难治性和进行性转移的分子靶向治疗的适当适应症。

著录项

  • 来源
    《Endocrine journal》 |2014年第8期|821-824|共4页
  • 作者单位

    Department of Surgery, Clinical Trial Management Center, Kuma Hospital, 8-2-35, Shimoyamate-Dori, Chuo-ku, Kobe 650-0011, Japan;

    Clinical Trial Management Center, Kuma Hospital, Kobe 650-0011, Japan;

    Department of Internal Medicine, Kuma Hospital, Kobe 650-0011, Japan;

    Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan;

    Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan;

    Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan;

    Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan;

    Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan;

    Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan;

    Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Differentiated thyroid carcinoma; Metastasis; RAI-refractory; Prognosis;

    机译:分化型甲状腺癌;转移;RAI耐火材料;预后;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号